About: http://data.cimple.eu/news-article/92ed349957dba9958094173ec099160f9ac3e71aa96b02b93d2f976d

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/92ed349957dba9958094173ec099160f9ac3e71aa96b02b93d2f976d Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Swiss pharmaceuticals giant Roche joined forces Wednesday with Regeneron to scale up supply of the US firm's REGN-COV2 medicine -- potentially both a prevention and treatment for COVID-19 infection. The two companies are teaming up to develop, manufacture and distribute the investigational combination of two antiviral antibodies. The product "could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus", Roche said in a statement. The medicine is being tested on humans in clinical trials for the treatment of COVID-19, and for the prevention of the new coronavirus in household contacts of infected individuals. If it proves safe and effective and regulatory approvals are granted, Regeneron will distribute the product in the United States, while Roche will do the same in the rest of the world. "We are excited about the potential for one medicine to serve both as a treatment for those infected, as well as protection for people exposed to the virus. REGN-COV2 could be a critical line of defence against the COVID-19 pandemic," said Roche Pharmaceuticals chief executive Bill Anderson. The collaboration should more than triple the current supply capacity of REGN-COV2, said Roche, with the potential for further expansion. Regeneron scientists designed REGN-COV2 specifically to block the infectivity of SARS-CoV-2, the virus which causes COVID-19. In technical terms, the two virus-neutralising antibodies that form REGN-COV2 "bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment". rjm/nl/spm
schema:headline	Roche, Regeneron partner on coronavirus antibody cocktail
schema:mentions	Cell surface receptor Cocktail Hoffmann-La Roche Mutation Antiviral drug Medication Protein Antibody Switzerland Pandemic Virus United States Coronavirus Severe acute respiratory syndrome coronavirus 2 The Meat Purveyors
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-08-19 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	88 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software